DAVID ALLISON

David Allison is a highly respected Managing Director at Westlake Village BioPartners, a leading venture capital firm renowned for its strategic investments in the life sciences sector. At Westlake Village BioPartners, Allison is instrumental in the firm's mission to create and support innovative biotechnology companies, focusing on early-stage therapeutic development that addresses significant unmet medical needs. His leadership helps guide promising scientific discoveries from concept to clinical reality, shaping the future of medicine.

Allison's investment focus areas are deeply rooted in cutting-edge biotechnology and drug discovery. He targets companies developing novel therapeutic platforms, innovative drug candidates, and disruptive technologies across various disease areas, including oncology, immunology, neurology, and rare diseases. His expertise lies in evaluating the scientific merit, clinical potential, and market viability of early-stage ventures, often taking an active role in company formation and strategic guidance. Westlake Village BioPartners, under his influence, seeks to build robust companies with strong scientific foundations and clear paths to patient impact.

Before his tenure at Westlake Village BioPartners, Allison built a distinguished career marked by significant contributions to the biotech industry. He was a Partner at Versant Ventures, where he co-founded Westlake Village BioPartners as a spin-out, demonstrating his entrepreneurial vision and commitment to specialized life science investing. Prior to his venture capital roles, Allison held a key position as Vice President of Business Development at Amgen, one of the world's largest biotechnology companies. At Amgen, he was responsible for evaluating and executing strategic transactions, including mergers, acquisitions, and licensing agreements, which provided him with invaluable experience in corporate strategy, deal-making, and drug development pipelines. This background at a major pharmaceutical player equipped him with a comprehensive understanding of the entire drug development lifecycle, from preclinical research to commercialization.

Allison's impact is evident through his involvement with numerous successful biotech ventures. He currently serves on the boards of several innovative companies, including Acelyrin, Amolyt Pharma, Janux Therapeutics, Lycia Therapeutics, Neumora Therapeutics, Rona Therapeutics, and Septerna, guiding their strategic growth and development. His past board memberships include Black Diamond Therapeutics, Inception Therapeutics (acquired by Roche), Jecure Therapeutics (acquired by Roche), Monte Rosa Therapeutics, Quanta Therapeutics, and Therini Bio, many of which have achieved significant milestones or successful exits. These engagements highlight his ability to identify and cultivate companies that deliver substantial value and advance medical science.

David Allison's career trajectory underscores his profound expertise in the life sciences investment landscape. His strategic vision, combined with a deep scientific understanding and extensive operational experience, positions him as a pivotal figure in the biotechnology venture capital community. Through his work at Westlake Village BioPartners, he continues to champion the development of transformative therapies, driving innovation that promises to improve global health outcomes.